De Motu Cordis are proud to be featured in the Saturday edition of the Courier Mail (March 15th, 2025).
Senior reporter, Rachel Riley, visited the De Motu Cordis Windsor Head Office to meet with the team. On the day, she toured the onsite pilot production facility, learnt about the dry powder inhaler platform and product development to date. This included product stability data which currently shows potential for an impressive shelf life.
Detail on the clinical program conducted to date was also presented along with DMC’s plans, currently underway, for a further pilot trial in allergy patients, a first for the company.
CEO, Peter O’Neill shared plans for an upcoming capital raise to ensure the ongoing development of the inhaler platform, whilst Prof. John Fraser AO gave his vision for building biotech manufacturing capabilities here in QLD with the help of local funding.
All these topics and more are covered in detail in the Courier Mail article attached below for viewing.
About DMC
“DMC is a clinical stage pharma company.”
DMC was founded in Brisbane, Australia by Professor John Fraser, an Intensivist and groundbreaking clinician, researcher, and company founder. John is also founder of the Critical Care Research Group and is a co-founder of BIVACOR Pty Ltd. John co-founded the COVID-19 Critical Care Consortium that facilitated collecting over 35 million data points from ICU units worldwide and aided in the development of treatment pathways.
Since inception, DMC has raised over US $21m in Seed rounds primarily in Australia. The majority of funding to date have been secured via the Queensland Business Development Fund, high net worth individuals and Australian family offices. A Series A financing round is planned for H2 2025, which will ideally be anchored by a US based VC.
This week our Company Founder Professor John Fraser presented to ICU intensivists and clinicians at Cleveland Clinic in Abu Dhabi.
He outlined the latest thinking in ICU care and described concepts on the ICU room of the future, specifically designed to shorten required ICU care and improving patient outcomes.
De Motu Cordis is proud to be featured in the Saturday edition of the Courier Mail (March 15th, 2025).
De Motu Cordis grows its IP portfolio to 28 patents, fortifying innovations in emergency medicine for anaphylaxis with their drug-device dry powder inhaler.